News

This agreement was secured in anticipation of Boston Therapeutics’ anticipated IND filing in late 2014, as well as the company’s planned international Phase III trial for BTI-320 that

In addition to accessing the drug via specialty distribution, Eli Lilly made the decision to offer physicians and healthcare practices the opportunity to order CYRAMZA through Biologics as

New pre-clinical data were presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW), held 3 May to 6 May 2014 in Chicago, Illinois. ALN-AAT is one

The investment, which will increase site capacity by more than 20%, comes two years after the company expanded the capacity of its MDI facility in Northridge, California, and

Triglycerides are a type of fat found in blood and an important energy source for the body. According to the company, EPANOVA is the first FDA approved prescription

Selexys develops drugs that target certain underlying mechanisms of inflammatory diseases and cancer. SELK2 is an investigational humanized monoclonal antibody designed to treat Crohn’s Disease and Multiple Myeloma.

The project is aimed at exploring a genetic cause in hereditary forms of the disease as a platform for developing disease-modifying treatment that would slow or stop the

Both the companies have not disclosed the financial details of the agreement, which is for an initial term of three years. Cardiome chief commercial officer Karim Lalji said

Dr. Huib Ovaa is principal investigator of Chemical Biology Laboratories at NKI and a member of FORMA’s deubiquitinase (DUB) investigator network. As part of the deal, FORMA and